No Data
No Data
Express News | Baicheng Medicine: Technology transfer of class 2 modified new drug 2022HY052, with an amount of 70 million yuan.
Express News | Baicheng Pharmaceutical established a biomedical technology company in Zhejiang.
Baicheng Pharmaceutical (301096): Leading the imitation and creation of the CRO industry and driving long-term development with a diversified layout.
In the previous article "In-depth Report on the CRO Industry of Pharmaron - Meeting Multi-level Customer Needs, Exploring the Performance Drivers of the Pharmaron CRO Sector", we explored the sustainability of Pharmaron CRO's growth, in which Baicheng Pharma has the most comprehensive capabilities.
Baicheng Pharmaceutical (301096.SZ) 2023 annual equity distribution: 3 yuan for every 10 shares, share registration on May 31
Baicheng Pharmaceutical (301096.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Pacific Securities: The pharmaceutical industry is under short-term pressure, and future policies will be frequent or enhance the certainty of clinical CRO benefits
With the end of the Fed's interest rate hike cycle, gradual easing of liquidity is expected to bring about a recovery in investment and financing, and overseas demand will improve ahead of local demand; future innovative drug support policies may be introduced intensively, and clinical CRO benefits are highly certain.
Express News | Baicheng Pharmaceutical: BIOS2220 Receives Clinical Trial Approval Notice
No Data